LIVE WEBINAR: Tuesday, February 2, 2021, 5:00 PM – 6:00 PM Eastern Time

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Bladder Cancer and Renal Cell Carcinoma

Join us on Tuesday, February 2nd for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Sumanta K Pal, MD
Clinical Professor, Department of Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California



David I Quinn, MBBS, PhD
Medical Director
USC Norris Cancer Hospital and Clinics
Head, Section of GU Cancer, Division of Oncology
Associate Professor of Medicine
USC Norris Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Bristol-Myers Squibb Company, Exelixis Inc and Seagen Inc.

Tuesday, February 2, 2021
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

Module 1: Current and Emerging Strategies in the Management of Urothelial Bladder Carcinoma (UBC)

  • FDA approval and integration into current clinical practice of pembrolizumab for patients with BCG-unresponsive, high-risk non-muscle-invasive UBC who are ineligible for or elected not to undergo cystectomy
  • Available data and ongoing trials with anti-PD-1/PD-L1 antibodies alone or in combination with other agents for localized UBC (eg, KEYNOTE-676, ALBAN, POTOMAC, NIAGARA)
  • Key efficacy and safety results from the Phase III JAVELIN Bladder 100 trial evaluating first-line maintenance therapy with avelumab; recent FDA approval and current clinical role
  • Design, eligibility criteria and efficacy and safety findings from the Phase III IMvigor130 trial assessing atezolizumab in combination with chemotherapy for previously untreated locally advanced or metastatic UBC
  • Ongoing Phase III trials (eg, CheckMate 901, NILE) evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies
  • FDA approval of enfortumab vedotin for patients with locally advanced or metastatic UBC; optimal integration into current management algorithms
  • Published efficacy findings with and FDA breakthrough therapy designation for enfortumab vedotin in combination with pembrolizumab for patients with locally advanced or metastatic UBC
  • Mechanism of action of erdafitinib and efficacy and safety data supporting the recent FDA approval of this agent for patients with locally advanced or metastatic UBC with susceptible FGFR3 or FGFR2 genetic alterations who have experienced disease progression on or after chemotherapy
  • Published research and ongoing evaluation of other promising agents and strategies in UBC (eg, sacituzumab govitecan, cabozantinib, novel FGFR inhibitors)

Module 2: Optimizing Treatment Approaches for Patients with Renal Cell Carcinoma (RCC)

  • Clinical and biologic factors in the selection of first-line therapy for patients with newly diagnosed metastatic RCC
  • Major efficacy and safety findings from the pivotal Phase III CheckMate 214 trial evaluating nivolumab/ipilimumab versus sunitinib for treatment-naïve advanced RCC
  • Design, eligibility criteria and key efficacy and safety data from the Phase III KEYNOTE-426 and JAVELIN Renal 101 trials assessing pembrolizumab/axitinib and avelumab/axitinib, respectively, in the front-line setting
  • Emerging results from the Phase III CheckMate 9ER trial evaluating nivolumab in combination with cabozantinib for previously untreated advanced RCC; potential role in clinical practice
  • Biologic rationale and research findings leading to the FDA breakthrough therapy designation for pembrolizumab/lenvatinib
  • Other ongoing Phase III studies (CLEAR, PDIGREE, COSMIC-313) investigating first-line immunotherapy/tyrosine kinase inhibitor combinations for advanced RCC
  • Clinical trial findings with cabozantinib and optimal use for patients with relapsed/refractory RCC; available data with and ongoing evaluation of cabozantinib in combination with atezolizumab after disease progression on immune checkpoint inhibitor-based therapy
  • Rational sequencing of available therapies for metastatic RCC progressing on prior therapies
  • Published research data with lenvatinib/everolimus and optimal integration into RCC management algorithms
  • Available clinical trial data and ongoing research with other novel agents and strategies for treatment-naïve and relapsed/refractory metastatic RCC

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of bladder cancer and renal cell carcinoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider emerging research and available guidelines to individualize first-and later-line therapy for patients with advanced renal cell carcinoma (RCC).
  • Recall the underlying research database supporting the FDA approval of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for metastatic RCC (mRCC), and develop strategies to appropriately integrate this approach into patient care.
  • Appraise available clinical trial data evaluating recently FDA-approved anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for previously untreated mRCC, and counsel patients about the risks and benefits of these novel regimens.
  • Develop a rational therapeutic approach to the sequencing of systemic therapies for patients with advanced RCC whose disease progresses on first-line treatment, incorporating tyrosine kinase inhibitors, mTOR inhibitors and immunotherapeutic agents.
  • Consider the recent FDA approval of pembrolizumab for high-risk, non-muscle-invasive urothelial bladder carcinoma (UBC) that is unresponsive to BCG, and determine how pembrolizumab can be appropriately integrated into patient care.
  • Evaluate available data and ongoing trials investigating the use of anti-PD-1/PD-L1 antibodies as neoadjuvant or adjuvant therapy for muscle-invasive bladder cancer, and refer eligible patients for appropriate study participation.
  • Review available clinical trial data leading to the recent FDA approval of the anti-PD-L1 antibody avelumab as maintenance therapy after first-line chemotherapy for patients with previously untreated metastatic UBC, and optimally incorporate this novel strategy into management algorithms.
  • Assess available and emerging clinical trial data evaluating anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with previously untreated metastatic UBC, and consider the potential role of this approach in routine practice.
  • Recognize the FDA approval of erdafitinib for advanced UBC with susceptible FGFR3 or FGFR2 genetic alterations in patients whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy, and determine how this agent may be appropriately integrated into clinical practice.
  • Recall the mechanism of action and pivotal clinical trial findings with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.
  • Appraise available research data and ongoing clinical trials evaluating novel agents and strategies for patients with RCC and UBC, and counsel appropriately selected individuals about participation in active research protocols.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Pal has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr QuinnAdvisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Merck, Pfizer Inc: Data and Safety Monitoring Board/Committee: Eisai Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Exelixis Inc and Seagen Inc.